Product name

Summary

Organization name

Profile

Aim of the invention is the diminishment of delayed graft function in the first postoperative days. By a singular peri-operative application of the anti-IL6 receptor antibody a dramatical reduction of the serum creatinin concentration and recovery of primary kidney function was achieved. A higher serum creatinin level and thus an elevated IL6 level is a typical symptom after a transplant operation.

The main reason for delayed graft function is a high body weight difference between donor and recipient. Experimental data were obtained with a rat models. Serum creatinin concentrations were higher in animals which received a transplant from much heavier donors. The effect was not observed in animals treated with a 500 μg dosis of anti-IL6 receptor antibody.

Advantages 

• Adressing a high medical need 
• Treatment of risk transplantation patients
• Improved graft function in weight-mismatched combinations

US patent application was filed. The invention was made at the Charité-University Hospital of Humboldt University Berlin and is offered by IPAL.

Contact

IPAL GmbH 
Dr. Christian Wunsch
christian.wunsch(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.                

Description File

URL

Your feedback

back